Rho GTPase activating protein 10Genealiases: GRAF2 · PS-GAP · PSGAP
Q-omics provides the consensus-scored ARHGAP10 profile across patient tissues and cancer cell-line models. ARHGAP10 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ARHGAP10 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, ARHGAP10 protein abundance shows 23,557 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, BLCA, and GBM as cancer lineages where ARHGAP10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARHGAP10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARHGAP10 survival associations across molecular data types. ARHGAP10 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARHGAP10 RNA expression–survival associations across cancer types. High ARHGAP10 expression shows unfavorable associations in MESO, HNSC, COAD and UVM, but favorable associations in KIRC and ESCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ARHGAP10 RNA expression.
This table summarizes ARHGAP10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ARHGAP10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARHGAP10 shows lower tumor expression in BLCA, KICH, UCEC, LIHC and BRCA and higher tumor expression in KIRC. The BLCA box plot shows higher ARHGAP10 RNA expression in normal versus tumor tissue (log2 FC = −1.932, t-test p < 0.001).
This table shows molecular features associated with ARHGAP10 in patient tissues and cancer cell lines. In patient samples, ARHGAP10 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ARHGAP10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BONE.
